KRTX (Karuna Therapeutics Inc) Net earnings per one share for the last twelve months

The TTM YoY earnings per share growth rate, as calculated by GURU.Markets quotes, stands at -47.50. Karuna Therapeutics (KRTX) develops cutting-edge schizophrenia treatments protected by patents and FDA approval. The uniqueness of the KarXT therapy eliminates side effects, guaranteeing pricing power. Experienced management successfully integrated the company into the structure of a pharma behemoth, earning the full confidence of investors through its historical track record.
KRTX (Karuna Pharma): analytical breakdowns and indicator data

Fundamental asset selection requires an analysis of profit dynamics to confirm business sustainability. This metric measures the percentage change in net income per share over a rolling year, neutralizing quarterly volatility. For Karuna Therapeutics (KRTX), this growth reflects the commercial efficiency of innovations in psychopharmacology and the success of joint research. Investors should interpret the EPS YoY TTM growth efficiency indicator as a gauge of the scalability of schizophrenia therapy. A positive trend confirms the capitalization of the company's scientific achievements.